(Q44051009)

English

Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-α antagonist therapy

scientific article published in December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-α antagonist therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

Akiko Kowada

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

1 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Molecular Diagnosis and Therapy

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

367-373

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

https://scigraph.springernature.com/pub.10.1007/bf03256394

0 references

Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Screening for tuberculosis infection prior to initiation of anti-TNF therapy

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Cost Effectiveness of Interferon-Gamma Release Assay versus Chest X-Ray for Tuberculosis Screening of BCG-Vaccinated Elderly Populations

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Cost-effectiveness of isoniazid chemoprevention in close contacts

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions?

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Priorities for the Treatment of Latent Tuberculosis Infection in the United States

1 reference

https://api.crossref.org/works/10.1007%2FBF03256394

21 January 2018

Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population

1 reference

https://pubmed.ncbi.nlm.nih.gov/21275454

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/21275454

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21275454

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/21275454

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/21275454

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21275454

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings]

1 reference

https://pubmed.ncbi.nlm.nih.gov/21275454

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/21275454

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relapse rate of tuberculosis treated with standard regimen of chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21275454

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21275454

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF03256394

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44051009&oldid=2106023789"